interleukin-15 enhanced TRuC-T

**Interleukin-15 enhanced TRuC-T** refers to an investigational next-generation **autologous TRuC T-cell therapy** format in which T cells engineered with a **T-cell receptor fusion construct** are further modified to co-express a **membrane-tethered interleukin-15 and IL-15 receptor alpha fusion protein**, with the aim of improving expansion, persistence, stem-like memory phenotype, tumor infiltration, and resistance to exhaustion in solid tumors. The term has been used in preclinical work from **TCR2 Therapeutics**, later part of **Adaptimmune**, across more than one TRuC program rather than as a single uniquely defined product; published examples include **mesothelin-targeted TC-210 gavo-cel enhanced with IL-15 fusion protein** and the **CD70-targeted TRuC candidate ADP-520** incorporating constitutive membrane-bound IL-15 signaling. Mechanistically, antitumor activity comes from **antigen-specific TRuC engagement through the endogenous TCR complex** combined with **local autocrine juxtacrine IL-15 signaling** that supports T-cell survival and memory differentiation. Because the queried name denotes a platform-style engineered cell-therapy variant rather than one unambiguous clinical product, it is best treated as a **non-specific TRuC-T cell therapy concept in preclinical or early development for solid tumors and selected hematologic malignancies**.

Other names

IL-15 enhanced TRuC-TIL15 enhanced TRuC-TIL 15 enhanced TRuC-TIL-15fu-enhanced TRuC-TIL15fu-enhanced TRuC-TIL 15fu-enhanced TRuC-TmbIL-15-enhanced TRuC-TmbIL15-enhanced TRuC-TmbIL 15-enhanced TRuC-Tmembrane-bound IL-15 enhanced TRuC-T